



A monthly report summarizing the Life Science transactions and trends in Washington State.

Washington State Transactions

Washington State Transactions by Industry



2015 Highlights

- Washington's robust immuno-oncology cluster, including adaptive immunotherapies, diagnostics and enabling technologies, continues to grow. Immuno-oncology transactions are up 6.9x from 2013.
- Investment in **pharmaceutical** companies up 5.7x from 2013, totaling over \$2.3B
- Medical technology** transactions are up 1.8x from 2013, totaling over \$595M
- Over \$170M in **digital health/HIT** transactions, up 2.7x from 2013

Pharmaceuticals

Top 5 Deals:

- Juno Therapeutics** \$1B (Partnership | Celgene)
- Seattle Genetics** \$525M (Second Public Offering)
- Dendreon** \$495M (Acquisition | Valeant Pharmaceuticals)
- Alder Biopharmaceuticals** \$200M (Second Public Offering)
- Nohla Therapeutics** \$21M (Venture Capital)

Medical Technology

Top 5 Deals:

- RF Surgical Systems** \$235M (Acquisition | Medtronic)
- Adaptive Biotechnologies** \$195M (Series F | Matrix Capital)
- Adaptive Biotechnologies** \$94M (Series E)
- Cardiac Dimensions** \$15M (VC | Arboretum Ventures, Aperture Venture Partners, Life Science Partners, Lumira Capital, M.H. Carnegie & Co)
- Kona Medical** \$10M (Debt)

Digital Health/HIT

Top 5 Deals:

- Remote Medical International** \$95M (Contract | USAID)
- Arivale** \$36M (Series B | ARCH Venture Partners, Polaris Partners, Maveron)
- Carena** \$13M (Series B | Cambia Health Solutions, Martin Ventures, McKensson Ventures)
- Navigating Cancer** \$6.6M (VC | Merck Global Health Innovation Fund, ORIX USA Corporation, Rustic Canyon Partners)
- InDemand Interpreting** \$4M (VC | Fifth Province Ventures, Health Enterprise Partners)

2015 Deal Highlights

Washington-based Life Science Transactions 2015

Date	Company	Type	Amount	Date	Company	Type	Amount
01/22/15	Alder Biopharmaceuticals	Second public offering	\$203,600,000	06/29/15	Nexgenia	Equity	\$1,617,582
01/22/15	Adaptive Biotechnologies	Series E	\$93,750,000	06/30/15	Vera Whole Health, Inc	Debt	\$2,000,000
01/28/15	Vesiflo	Convertible note	\$650,000	07/13/15	Arivale	Series B	\$36,000,000
01/30/15	MalarVx, Inc	Equity	\$110,000	07/14/15	Cytodyn	Equity	\$1,972,500
02/05/15	Alpine Immune Sciences	Seed	\$1,300,000	07/14/15	RF Surgical Systems	Acquisition	\$235,000,000
02/05/15	M3 Biotechnology	Equity	\$150,000	07/21/15	Deep Domain	Equity	\$260,507
02/10/15	Valant Medical Solutions	Venture Equity	\$285,350	07/31/15	Qliance Medical Management	Debt	\$2,676,730
02/13/15	Stasys Medical	Series A	\$160,000	08/07/15	Precision Image Analysis	Equity	\$60,348
02/18/15	StratoScientific	Venture Equity	\$550,000	08/11/15	Vicis	Venture Equity	\$1,500,000
02/23/15	Dendreon	Acquisition	\$495,000,000	08/12/15	Marina Biotech	Equity	\$1,100,000
03/06/15	Cerevast Therapeutics	Series C	\$1,375,000	08/13/15	Bloomingtondale Memory Care	Equity	\$3,373,525
03/09/15	KinDex Pharmaceuticals	Series A	\$500,000	08/17/15	OtoNexus Medical Technologies	Debt	\$754,990
03/11/15	Cardiac Dimensions	Venture Equity	\$15,200,000	08/18/15	Immusoft	Debt	\$375,000
03/15/15	Medical Mirror Systems	Equity	\$250,000	08/19/15	Sound Pharmaceuticals	Debt	\$300,000
03/19/15	Nortis	Venture Equity	\$408,845	08/21/15	Navigating Cancer	Venture Equity	\$6,605,573
03/20/15	Healthentic	Series C	\$3,750,000	08/28/15	Aqueduct Critical Care	Equity	\$3,712,304
03/20/15	StratoScientific	Venture Equity	\$150,000	09/02/15	Kona Medical	Debt	\$10,000,300
03/25/15	Cadence Biomedical	Equity	\$959,578	09/14/15	Seattle Genetics	Second public offering	\$525,000,000
04/08/15	NuvoMed	Equity	\$390,637	09/14/15	Impel Neuropharma	Equity	\$1,257,927
04/10/15	Cardeas Pharma	Series B	\$3,500,000	09/18/15	Impel Neuropharma	Equity	\$4,000,000
04/13/15	Carena	Debt	\$500,000	09/21/15	Cardiac Insight	Undisclosed	\$3,500,000
04/17/15	X2 Biosystems	Venture Equity	\$350,000	09/22/15	Just Biotherapeutics	Series A	\$15,000,000
04/23/15	Deep Domain	Venture Equity	\$30,000	09/24/15	VDA Pharma	Debt	\$55,000
04/24/15	Mpirica Health	Series A	\$1,600,000	09/24/15	Joylux	Seed	\$3,000,000
05/01/15	Mirabilis Medica	Debt	\$2,920,000	09/30/15	Accelerator Corporation	Venture Equity	\$11,700,000
05/06/15	Adaptive Biotechnologies	Series F	\$195,000,000	10/02/15	Spitac Genetics	Debt	\$200,000
05/06/15	Theraclone Sciences	Venture Equity	\$3,080,000	10/04/15	Cytodyn	Equity	\$2,693,800
05/06/15	Cyrus Biotechnology	Debt	\$850,000	10/15/15	Global Health Vaccine Center of Innovation	Partnership	\$9,500,000
05/06/15	InDemand Interpreting	Venture Equity	\$4,000,000	10/19/15	Novuson Surgical	Equity	\$500,000
05/14/15	Cytodyn	Debt	\$3,281,050	10/27/15	Alpine Immune Sciences	Partnership	\$5,000,000
05/18/15	Tissue Regeneration Systems	Debt	\$2,093,182	10/27/15	Park Boulevard Memory Care, LLC	Equity	\$3,524,925
05/19/15	KPI Therapeutics	Equity	\$27,000	10/30/15	Methex Therapeutics	Equity	\$90,000
05/21/15	Ventec Life Systems	Venture Equity	\$8,192,480	11/04/15	Clarity Health	Acquisition	Undisclosed
05/27/15	BioViva USA	Equity	\$250,000	11/11/15	Aminex Therapeutics	Series A	\$4,000,000
06/02/15	C-SATS	Venture Equity	\$2,500,000	11/11/15	Mpirica Health	Venture Equity	\$400,000
06/03/15	Magnolia Medical Technologies	Venture Equity	\$6,235,322	11/13/15	Qliance Medical Management	Equity	\$450,000
06/04/15	Carena	Series B	\$13,300,000	11/16/15	Implicit Bioscience	Equity	\$50,800
06/05/15	Valant Medical Solutions	Venture Equity	\$3,000,000	11/20/15	M3 Biotechnology	Equity	\$3,500,000
06/11/15	Glycostasis	Equity	\$149,998	11/25/15	OtoNexus Medical Technologies	Debt	\$1,403,080
06/16/15	Altius Institute for Biomedical Sciences	Partnership	\$95,000,000	12/01/15	Universal Cells	Partnership	\$5,500,000
06/16/15	Remote Medical International	Partnership	\$95,000,000	12/04/15	Breast Microseed	Debt	\$500,000
06/17/15	Stratos Genomics	Series B	\$19,999,976	12/16/15	Matrix Genetics	Debt	\$1,600,000
06/20/15	Global Innovation Exchange	Partnership	\$45,000,000	12/23/15	Switch Healthcare	Equity	\$300,000
06/20/15	Vicis	Seed	\$1,600,000	12/24/15	Nohla Therapeutics	Equity	\$21,000,000
06/22/15	Qliance Medical Management	Debt	\$520,753	12/24/15	Nativis	Equity	\$250,000
06/24/15	Nativis	Venture Equity	\$725,000	12/29/15	PhaseRx	Debt	\$4,000,000
06/24/15	Cadence Biomedical	Series B	\$1,200,000				
06/25/15	Blaze Bioscience	Equity	\$85,400				
06/28/15	Juno Therapeutics	Partnership	\$1,000,000,000				
				2015 Total			\$3,263,814,462

Check out the previous 2015 issues of the Washington Life Science Report highlighting:

**Venture Capital
Activity**



Digital Health/HIT



**Immuno-oncology
Cluster**



**Partnership/M&A
Activity**



Medical Technology

